NCT00753298

Brief Summary

The study is designed as a randomized, double-blind, parallel-group, multi centre study comparing perception and tolerability of investigational product and comparator. In the randomized part of the study the subjects will be given either LoFric Primo (POBE) or the comparator LoFric Primo (PVC) for use over 4 weeks. The hypothesis is that subject perception and satisfaction of POBE is equal to or better than for PVC.

Trial Health

93
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
195

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jan 2007

Geographic Reach
6 countries

13 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2007

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2008

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

September 15, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 16, 2008

Completed
9 months until next milestone

Results Posted

Study results publicly available

June 2, 2009

Completed
Last Updated

November 11, 2021

Status Verified

September 1, 2012

Enrollment Period

1.2 years

First QC Date

September 15, 2008

Results QC Date

April 6, 2009

Last Update Submit

November 10, 2021

Conditions

Outcome Measures

Primary Outcomes (6)

  • Subject's Perception Regarding Handling of Test Catheter Before Insertion

    Subject's perception regarding handling of test catheter before insertion, measured by mean score on a scale from 1 (Easy) to 5 (Troublesome)

    At 4 weeks

  • Subject's Perception Regarding Handling of Test Catheter at Insertion

    Subject's perception regarding handling of test catheter at insertion, measured by mean score on a scale from 1 (Easy) to 5 (Troublesome)

    At 4 weeks

  • Subject's Perception Regarding Handling of Test Catheter at Withdrawal

    Subject's perception regarding handling of test catheter at withdrawal, measured by mean score on a scale from 1 (Easy) to 5 (Troublesome)

    At 4 weeks

  • Subject's Perception Regarding Handling of Test Catheter After Withdrawal

    Subject's perception regarding handling of test catheter after withdrawal, measured by mean score on a scale from 1 (Easy) to 5 (Troublesome)

    At 4 weeks

  • Subject's General Satisfaction With Test Catheter

    Subject's general satisfaction with test catheter, measured by mean score on a scale from 1 (Very satisfied) to 5 (Absolutely not satified)

    At 4 weeks

  • Subject's Sensation When Using Test Catheter

    Subject's sensation when using test catheter, measured by mean score on a scale from 1 (Comfortable) to 6 (Severe pain)

    At 4 weeks

Study Arms (2)

LoFric Primo (POBE) single-use urinary catheter

EXPERIMENTAL
Device: LoFric Primo (POBE) single-use urinary catheter

LoFric Primo (PVC) single-use urinary catheter

ACTIVE COMPARATOR
Device: LoFric Primo (PVC) single-use urinary catheter

Interventions

LoFric Primo (POBE) single-use urinary catheter

LoFric Primo (POBE) single-use urinary catheter

LoFric Primo (PVC) single-use urinary catheter

LoFric Primo (PVC) single-use urinary catheter

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Provision of informed consent
  • Males and females aged 18 years and over
  • Experienced users of LoFric Primo with a minimum of one month of use
  • Practice CIC with LoFric Primo at least 3 times per day
  • Adults able to read, write and understand information given to them regarding the study

You may not qualify if:

  • Ongoing symptomatic UTI
  • Suspicions of possible poor compliance with CIC during the study period
  • Previous enrolment or randomisation of treatment in the present study
  • Pregnancy
  • Subjects not able to perform self-catheterisation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (13)

Medical University of Vienna, Department of Urology

Vienna, A-1090, Austria

Location

NRZ Greifswald

Greifswald, 17487, Germany

Location

Kliniken Maria Hilf GmbH, Zentrum für Kontinenz und Neuro-Urologie, Krankenhaus St. Franziskus

Mönchengladbach, 41063, Germany

Location

BG-Klinik Tübingen

Tübingen, 72076, Germany

Location

Ospedale Careggi, Unità Spinale

Florence, 50139, Italy

Location

Primario U.O. Neuro-Urologia, Direttore Dipartimento delle Mielolesioni

Torino, Italy

Location

Ziekenhuis Lievensberg, Afdeling Urologie

Bergen op Zoom, 4624 VT, Netherlands

Location

Albert Schweitzer Ziekenhuis, Locatie Dordwijk

Dordrecht, 3300 AK, Netherlands

Location

Catharina Ziekenhuis

Eindhoven, 5602 ZA, Netherlands

Location

Radboud Univesity Nijmegen Medical Centre

Nijmegen, 6500 HB, Netherlands

Location

Verksamhet Urologi, Sahlgrenska Universitets sjukhuset

Gothenburg, 413 45, Sweden

Location

Sheffield Teaching Hospitals NHS Foundation trust, Royal Hallamshire Hospital

Sheffield, S10 2JF, United Kingdom

Location

Royal National Orthopaedic Hospital, Spinal Injuries Unit, Brockley Hill Stanmore

Stanmore, HA7 4LP, United Kingdom

Location

Results Point of Contact

Title
Head of Therapeutic Area Health Care
Organization
Astra Tech AB

Study Officials

  • Alfred J Witjes, Prof Dr

    Radboud Univesity Nijmegen Medical Centre

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 15, 2008

First Posted

September 16, 2008

Study Start

January 1, 2007

Primary Completion

March 1, 2008

Study Completion

March 1, 2008

Last Updated

November 11, 2021

Results First Posted

June 2, 2009

Record last verified: 2012-09

Locations